Three new lung cancer genetic biomarkers are identified in Dartmouth study

October 26, 2017, Dartmouth-Hitchcock Medical Center

Both environmental and genetic risk factors contribute to development of lung cancer. Tobacco smoking is the most well-known environmental risk factor associated with lung cancer. A Dartmouth research team led by Yafang Li, PhD, has conducted a study to display that gene-smoking interactions play important roles in the etiology of lung cancer.

In their study, three novel SNPs (single-nucleotide polymorphisms), or variations in our DNA that underlie our susceptibility to developing disease, were identified in the interaction analysis, including two SNPs for non-small cell lung cancer risk and one SNP for squamous cell lung cancer risk. The three identified novel SNPs provide potential candidate biomarkers for lung cancer risk screening and intervention. The team's findings, "Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population," have been published in Carcinogenesis.

The and phenotype data used in this analysis came from OncoArray Consortium. "Genome-wide interaction scanning remains a challenge as most genome-wide association studies are designed for main effect association analysis and have limited power for interaction analysis," said Li. "This study is by far the largest genome-wide SNP-smoking interaction analysis reported for lung cancer. We also adopted a two-step strategy in the analysis to reduce the power loss from ordinary gene-environment interaction analysis."

The three SNPs, identified in the team's study, stratify lung cancer risk by smoking behavior. These three SNPs can be potential biomarkers used to improve the precision to which researchers can categorize an individual's risk of cancer disease by smoking behavior, which are helpful for individualized prognosis and prediction of treatment plan.

While this reported study was restricted to a Caucasian population and the results may not be generalized to other ethnicities because of the different genetic backgrounds, the team aims to further test the identified interaction effect using genotype from other populations. "The limited overlap between discovery genotype and replication genotype may have reduced the power in our validation study," says Li. "We believe as more genotype data becomes available in the future we can discover more important gene-smoking interaction in disease."

Explore further: Largest genome-wide study of lung cancer susceptibility identifies new causes

More information: Yafang Li et al, Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population, Carcinogenesis (2017). DOI: 10.1093/carcin/bgx113

Related Stories

Largest genome-wide study of lung cancer susceptibility identifies new causes

June 13, 2017
Using the OncoArray genotyping platform developed by multiple cancer consortia, a recent large aggregated genomewide association study identifies new susceptibility loci for lung cancer, the leading cause of cancer mortality ...

Potential new asthma genes ID'd in genome-wide study

July 28, 2016
(HealthDay)—Potential new asthma genes have been identified in a genome-wide association study (GWAS) combined with subsequent lung expression quantitative trait loci (eQTL) analysis, according to research published online ...

Gene variant linked with reduced lung cancer risk

October 8, 2012
A variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer. That is the finding of an analysis published early online in Cancer, a peer-reviewed journal of the American ...

Genetic variants, tobacco exposure and lung cancer risk

April 25, 2012
There is an association between the rs1051730-rs16969968 genotype and objective measures of tobacco exposure, which indicates that lung cancer risk is largely, if not entirely, mediated by level of tobacco exposure, according ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.